RECURSION PHARMACEUTICALS, INC. (RXRX) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 54.86M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 52.94M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $54.86M | $52.94M | (m) |
| 2026-03-31 | (m) | $66.41M | $61.61M | (m) |
| 2025-12-31 | (m) | $74.68M | $70.95M | (m) |
| 2025-09-30 | (m) | $43.69M | $69.47M | (m) |
| 2025-06-30 | (m) | $64.60M | $66.86M | (m) |
| 2025-03-31 | (m) | $59.79M | $55.90M | (m) |
| 2024-12-31 | (m) | $58.84M | $45.24M | (m) |
| 2024-09-30 | (m) | $65.18M | $42.33M | (m) |
| 2024-06-30 | (m) | $49.63M | $41.12M | (m) |
| 2024-03-31 | (m) | $46.23M | $41.30M | (m) |
| 2023-12-31 | (m) | $44.58M | $42.59M | (m) |
| 2023-09-30 | (m) | $47.36M | $43.55M | (m) |
| 2023-06-30 | (m) | $49.99M | $48.08M | (m) |
| 2023-03-31 | (m) | $46.64M | $52.92M | (m) |
| 2022-12-31 | (m) | $39.84M | $48.27M | (m) |
| 2022-09-30 | (m) | $28.70M | (m) | (m) |
| 2022-06-30 | (m) | $18.07M | (m) | (m) |
| 2022-03-31 | (m) | $12.95M | (m) | (m) |
| 2021-12-31 | (m) | $10.18M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $3.96M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $2.32M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |